A recently discovered potential tumor suppressor protein, Zac1, was previously shown to promote cell cycle arrest and apoptosis, and to act as a positive or negative transcriptional cofactor for nuclear receptors. Since these activities are common to Zac1 and p53, we tested for a functional interaction between these two proteins by investigating possible eects of Zac1 on the transcriptional activator function of p53. Zac1 speci®cally enhanced the activity of p53-responsive promoters in cells expressing wild type p53. The same promoters were not activated by Zac1 in cells lacking functional p53, but the Zac1 eect was restored by co-expression of p53. Zac1 bound to p53 and enhanced the activity of p53 or its N-terminal transcriptional activation domain fused to the DNA binding domain of Gal4. These results indicate that Zac1 served as a transcriptional coactivator for p53. The enhancement of p53 activity by Zac1 was much more dramatic in HeLa cells than in other cell lines tested. HeLa cells express human papillomavirus type 18 E6 protein which inactivates and causes the degradation of p53. Physical and functional interactions observed between Zac1 and E6 protein indicated that the dramatic activity of Zac1 in HeLa cells was due not only to Zac1's coactivator eect on p53, but also to the ability of Zac1 to reverse E6 inhibition of p53. Oncogene (2001) 20, 2134 ± 2143.
Introduction
The transcription factor p53 is a multi-functional tumor suppressor protein involved in cellular responses to stress, including DNA damage, hypoxia, low ribonucleotide levels, and oncogene expression (May and May, 1999; Levine, 1997) . In response to these signals p53 can arrest the cell cycle, modulate the DNA repair process, or induce apoptosis. The mechanism of action for p53 in these roles involves protein ± protein interactions with key signaling proteins and the ability to bind speci®c enhancer elements in the promoters of target genes and thereby activate transcription. Suppression of the activity of p53 and other tumor suppressor proteins occurs in most human tumors. The most frequently observed mechanism for inactivation of p53 in tumors is by point mutations in its DNA binding domain.
Recently, a novel zinc ®nger protein, Zac1, was identi®ed along with p53 in a functional screening system by virtue of their common ability to induce expression of the type 1 pituitary adenylate cyclaseactivating polypeptide (PACAP) receptor gene (Spengler et al., 1997; Homann et al., 1998) . Zac1 exhibited an anti-proliferative activity characterized by induction of extensive apoptosis and G1 arrest, which proceeded independently of pRb and independently of the regulation of p21, p27, and p16 cell cycle control proteins (Spengler et al., 1997) . Zac1 is also a sequence-speci®c DNA binding protein and thus may be able to serve as a DNA-binding transcriptional regulator (Kas et al., 1998; Varrault et al., 1998) . We previously demonstrated that Zac1 can serve as a transcriptional coactivator or repressor of nuclear receptor activity in HeLa cells as well as other cell types (Huang and Stallcup, 2000) . Interestingly, p53 is also a strong repressor of nuclear receptor function (Bhat et al., 1997; Yu et al., 1997) . The mechanism of the nuclear receptor co-factor activity of Zac1 may involve its ability to bind directly to nuclear receptors, but Zac1 can also bind to two classes of nuclear receptor coactivators, the p160 coactivators and the CBP/p300 family of coactivators (Huang and Stallcup, 2000) . Whether Zac1 acted as a coactivator or repressor depended on the type of nuclear receptor, cell line, and reporter gene used in transient transfection experiments, suggesting that functional interactions with cell type-speci®c proteins markedly in¯uence the nature of Zac1 function.
Thus, Zac1 and p53 are both pleotropic regulators that have a number of similar activities: both regulate cell cycle, apoptosis, and nuclear receptors; and both interact physically and functionally with CBP and p300 which serve as integrators of multiple signaling pathways (Huang and Stallcup, 2000; May and May, 1999) . Both p53 and Zac1 are sequence-speci®c DNA binding proteins, and both can act as transcriptional co-factors for other transcriptional activator proteins. In addition, oncogenic proteins of many tumor viruses target p53 and perturb the cell cycle and apoptosis control pathways, in which both p53 and Zac1 are involved. The similar functions of Zac1 and p53 and their involvement in many of the same cellular processes led us to test for functional relationships between these two proteins. We therefore tested the eect of Zac1 on the expression of a reporter gene containing p53 response elements in various cell lines containing or lacking functional p53. This test was also conducted in HeLa cells, which have limiting p53 activity, due to the suppression of p53 protein level and activity by the human papillomavirus (HPV) type 18 E6 protein (E6.18) present in these cells (Schwarz et al., 1985; Werness et al., 1990; Schener et al., 1990; Matlashewski et al., 1986) . Our studies reveal that Zac1 serves as a transcriptional coactivator for p53 and can also reverse the inhibitory eect of the viral oncoprotein HPV E6.18 on p53 function.
Results

Zac1 functions as a coactivator for p53
The similar eects of p53 and Zac1 on cell cycle arrest and apoptosis led us to test for functional interactions between these proteins. Since p53 is a DNA-binding transcriptional activator, we tested the eect of Zac1 on the expression of a p53-responsive reporter plasmid, pG13-LUC, consisting of a polyomavirus basal promoter controlled by 13 copies of a consensus p53 response element. The tests were conducted in a matched pair of cell lines containing or lacking a functional p53 gene. In the human colon carcinoma cell line HCT116 p537/7 which lacks p53, Zac1 had no eect on the expression of pG13-LUC, but Zac1 enhanced expression of the same reporter gene eightfold in HCT116 p53+/+ cells ( Figure 1 ). Thus, Zac1 could not enhance expression of p53-responsive promoters unless p53 was present. These results are consistent with the conclusion that Zac1 acts as a coactivator for p53. Zac1 was previously shown to have a similar eect on nuclear receptors (Huang and Stallcup, 2000) .
We further tested whether the enhancement eect of Zac1 on the pG13 promoter and its requirement for functional p53 could also be observed in other human cell lines containing or lacking functional p53. HeLa, a cervical carcinoma line, and MCF-7, a breast adenocarcinoma, express wild type p53 (Matlashewski et al., 1986; Bartek et al., 1990; Tam et al., 1994; Casey et al., 1991) . In contrast, T-47D breast ductal carcinoma cells contain an inactive mutant form of p53 (Nigro et al., 1989; Runnebaum et al., 1991) , and MDAH041 ®broblasts from a Li ± Fraumeni syndrome patient lack p53 expression (Little et al., 1987) . In the two cell lines expressing wild type p53, expression of Zac1 caused a substantial enhancement in the activity of pG13-LUC (Figure 2b,d ). In contrast, Zac1 had little or no eect on pG13-LUC expression in the cell lines lacking functional p53 (Figure 2a,c ). Next, we tested whether exogenous expression of p53 could restore the eect of Zac1 in cells lacking endogenous functional p53. Exogenous p53 expression by transient transfection had little or no eect on pG13-LUC expression in cells already containing functional p53 (Figure 2b,d ) but caused a substantial enhancement of luciferase activity in cells lacking functional p53 (Figure 2a,c) . When cotransfected with Zac1, p53 further enhanced the eect of Zac1 on pG13-LUC activity in all four cell lines. However, the eective concentration range of p53 to achieve this synergy with Zac1 was often quite narrow.
Thus, in cells lacking functional p53, transfection of p53 expression vector caused a much stronger enhancement of pG13-LUC activity than transfection of Zac1 vector (Table 1 , lines A and C). In contrast, in cells that express endogenous functional p53, transfection of the Zac1 vector caused a stronger enhancement than transfection of p53 vector (Table 1, lines B and D) . When comparing the eect of Zac1 expression in the four cell lines, the maximum fold enhancement by Zac1 was similar in the two p53-negative cell lines and MCF-7 cells which express functional p53 (Table 1 , lines A ± C). However, these fold induction ®gures alone are somewhat misleading, because the activity of pG13-LUC in the absence of transfected Zac1 and p53 vectors is extremely low in the p53-negative cell line but relatively high in MCF-7 cells (Figure 2 ). For a more complete assessment of the Zac1 eect, one must also consider the net increase in luciferase activity caused by Zac1; this net increase is large in the p53-positive cells (Figure 2b,d ) and low in the cells lacking functional p53 (Figure 2a,c) . These ®ndings further support the conclusion that the enhancing eect of Zac1 on p53-responsive promoters requires the presence of functional p53, and that Zac1 is thus acting as a coactivator for p53.
Because the Zac1 eect was most robust in HeLa cells, we used the HeLa cell system to investigate further the mechanism of p53-responsive promoter Figure 1 Zac1 coactivator function on p53-responsive promoters in HCT cells requires p53. The indicated HCT116 cell line, expressing or lacking p53, was transiently transfected with 0.5 mg of pG13-LUC reporter plasmid and, where indicated, 0.5 mg of pSG5.HA-mZac1b. Luciferase activity was determined from the transfected cell extracts. Numbers above histograms are calculated relative to the ®rst histogram on the left of the ®gure activation by Zac1. We used two similar reporter plasmids, pG13-LUC and pMG15-LUC; pMG15-LUC has the same basal polyomavirus promoter as pG13-LUC but contains 15 mutant p53 response elements. While Zac1 enhanced pG13-LUC expression by almost 800-fold in HeLa cells, it failed to enhance the expression of pMG15-LUC (Figure 3a) . Furthermore, a C-terminal fragment of p53 (amino acids 301 ± 390) which can bind to wild type p53 and thereby exerts a dominant negative eect on wild type p53 function, almost completely eliminated the enhancement of pG13-LUC expression by Zac1 (Figure 3b ). This inhibition was reversed by over-expression of wild type p53. Thus, the stimulatory eect of Zac1 on promoter activity required the presence of functional p53 and p53 response elements. These results further supported the conclusion that Zac1 acted as a coactivator for p53. The dramatic enhancement of pG13-LUC expression by Zac1 in HeLa cells was speci®c for p53-responsive promoters: expression of a CMV-bgal reporter gene (bgalactosidase gene controlled by a cytomegalovirus promoter) was enhanced by only 2 ± 4-fold by various levels of Zac1 expression vector ( Figure 3c ) and expression of an SV40-bgal reporter gene was unaected by Zac1 (data not shown).
The pG13-LUC reporter gene is useful for studying p53 activity because it contains no regulatory elements other than the p53 response elements. However, since it is an arti®cial promoter, we also examined the eect of Zac1 on the p21 gene promoter, which is responsive to p53 (Wu and Schonthal, 1997) . In mouse embryo ®broblast cells lacking a functional p53 gene, Zac1 had no eect on expression of transiently transfected p21-LUC, a luciferase reporter gene controlled by the p21 gene promoter. Transfection of p53 expression vector enhanced p21-LUC expression 10-fold, and co-transfection of Zac1 vector with the p53 vector caused an additional sixfold enhancement ( Figure 4a ). In HeLa cells, which express low levels of endogenous functional p53, transfection of Zac1 and p53 vectors each enhanced p21-LUC expression (26-fold and 46-fold, respectively), and co-transfection of both vectors together caused a synergistic 230-fold enhancement of activity ( Figure 4a ). Transfection of p53 and Zac1 vectors into HeLa cells also enhanced expression of the native p21 gene, as seen by increased levels of p21 protein, while having no eect on expression of a control protein, CARM1, from its native gene ( Figure  4b ). Thus, Zac1 speci®cally enhanced expression of a natural p53-responsive promoter, both in its native gene and in a transiently transfected plasmid.
While the results presented are consistent with a coactivator role for Zac1, they could also be due to enhancement of p53 protein levels by Zac1, through increased p53 synthesis or decreased p53 turnover. Immunoblotting was used to test the eect of Zac1 on p53 protein levels. Since p53 levels in the transfected and untransfected cell lines used for our transcriptional activation studies (Figures 1 ± 4) were too low to be detected (data not shown), we used COS-7 cells to amplify the SV40-based plasmids encoding p53 and Figure 2 Eects of Zac1 on expression of a p53-responsive promoter in various cell lines containing or lacking wild type p53. The indicated cell lines containing wild type (wt), mutant (mut), or no p53 were transfected with reporter plasmid pG13-LUC (0.5 mg), and the amount of Zac1 (squares) or p53 (circles and triangles) expression plasmid indicated on the xaxis. In one set of assays (triangles) 0.5 mg of Zac1 expression plasmid was transfected with varying amounts of p53 plasmid. In a, c, and d all three curves have overlapping points on the y axis Zac1. Transfection of COS-7 cells with the same p53 vector used for the transcriptional activation studies produced detectable levels of p53, and the p53 level was not enhanced by co-expression of Zac1 ( Figure 5 ). These data support a role for Zac1 as a coactivator for p53 rather than an enhancer of p53 protein levels.
Zac1 has direct physical and functional interactions with p53
One possible mechanism for the coactivator function of Zac1 is through physical binding to p53. Full length p53 bound in vitro to a GST-Zac1 fusion protein immobilized on agarose beads (Figure 6a ), supporting the idea that the coactivator function of Zac1 involves direct binding to p53. p53 has an N-terminal transcriptional activation domain, a DNA binding domain in the center of the polypeptide chain, and a C-terminal region responsible for homo-tetramer formation and regulation of p53 activity (May and May, 1999) (Figure 6a ). Deletion of either the N-terminal p53 amino acids 1 ± 95 or the C-terminal amino acids 301 ± 390 did not cause loss of binding, but deletion of both the N-terminal and C-terminal regions eliminated binding. The N-terminal activation region of p53 (amino acids 1 ± 94) bound moderately to Zac1, but the C-terminal region (amino acids 301 ± 390) bound only weakly. Thus, Zac1 bound to the p53 N-terminal activation region or to the large C-terminal fragment consisting of the DNA-binding, oligomerization, and regulatory regions (Figure 6a ).
Since Zac1 binds directly to p53 and its activation domain, its coactivator eect might be through enhancement of the activity of the N-terminal transcriptional activation domain of p53. When full length p53 or the p53 activation domain (amino acids 1 ± 127) was fused to the yeast Gal4 DNA binding domain (DBD), each one was capable of activating transcription of a reporter gene containing Gal4 response elements. The N-terminal fragment of p53 had a stronger activity than full length p53, due to the removal of the C-terminal negative regulatory domain of p53 (Figure 6b ). Coexpression of Zac1 further enhanced the activity of the full length p53 fusion protein by fourfold and the activity of Gal4DBD-p53 1 ± 127 by 13-fold. These results indicate that Zac1 may enhance p53 function through direct binding to p53.
Why is Zac1 function so much more dramatic in HeLa cells than in other cells?
Zac1 had a much more dramatic eect on the pG13 promoter in HeLa cells (Figures 2d and 3a) than in any of the other cell lines tested (Figures 1 and 2) . One important dierence of HeLa cells compared with the other cell lines is the presence of HPV-18 proteins in HeLa cells. HPV E6 proteins inhibit p53 activity by multiple mechanisms:reduction of cellular p53 levels by speci®cally targeting p53 for degradation; and binding to p53 to prevent its binding to p53-responsive promoters (Thomas et al., 1999) . In addition, E6 proteins are known to bind to and inhibit the activity of CBP and p300 which also serve as coactivators for p53 (Patel et al., 1999; Zimmermann et al., 1999) . HeLa cells are known to contain very low levels of wild type p53 due to the E6-mediated degradation of p53 (Matlashewski et al., 1986) . Pathways leading to p53 activation are still known to be active in these cells, indicating that p53 is functional (Desaintes et al., 1997) . p53 levels in HeLa cells might be limiting for expression of pG13-LUC, and Zac1 might be acting to prevent p53 degradation. However, elevation of cellular p53 levels in HeLa cells could not entirely account for the coactivator eect of Zac1 on the pG13 promoter, since exogenous expression of p53 by transfection failed to reproduce the dramatic enhancement of pG13 promoter activity caused by Zac1 (Figures 2d and 3a) . Since elevation of p53 levels could not completely explain the dramatic eect of Zac1, we investigated whether Zac1 might reverse other inhibitory eects of HPV-18 E6 protein on p53 function, by testing for physical and functional interactions between Zac1 and E6.18 proteins.
In GST pull down assays, Zac1 and wild type p53 each bound to GST-E6.18 protein (Figure 7a ). When Zac1 and p53 were incubated together with GST-E6.18, the binding of Zac1 and the p53 proteins were both reduced slightly (right-hand lane), suggesting that Zac1 and p53 might compete for binding to E6.18 protein. To test further for competitive binding, labeled wild type p53 or p53 95 ± 390 was incubated with GST-E6.18 and increasing amounts of unlabeled recombinant His 6 -Zac1 protein (Figure 7b ). The highest level of His 6 -Zac1 protein used reduced the binding of the wild type or truncated p53 proteins to E6.18 protein by 5.7-fold and 15-fold, respectively. The inhibition of binding by the recombinant Zac1 protein was relatively speci®c, since the same amount of Zac1 protein only reduced binding of CBP to E6.18 protein by 2.5-fold. Thus, Zac1 speci®cally disrupted the p53-E6.18 complex, providing a possible mechanism for enhancement of p53 activity.
To test for a functional interaction between Zac1 and E6.18 proteins in transfected cells, we examined the eect of Zac1 on the autologous transcriptional activation activity of a Gal4DBD-E6.18 fusion protein.
For these studies we used HCT116 p53+/+ cells which contain wild type p53 but no HPV proteins. E6.18 protein fused to Gal4 DBD had an autologous *Net increase in luciferase activity due to Zac1 was very small (see Figure 2 ). **Net increase in luciferase activity due to Zac1 was very large (see Figure 2) transcriptional activation activity (Figure 8a , compare histograms 1 and 3). Zac1 strongly inhibited the activity of Gal4-E6.18 (histograms 3 ± 6). However, Zac1 had little or no eect on the low activity of Gal4 DBD (histograms 1 and 2). consistent with the hypothesis that part of the stimulatory eect of Zac1 on pG13-LUC activity in HeLa cells is due to Zac1's ability to disrupt the p53-E6.18 complex, thus restoring the activity of p53.
Discussion
Zac1 is a transcriptional coactivator for p53
Exogenous expression of Zac1 in transient transfection assays enhanced the activity of p53-responsive reporter genes, but only in the presence of functional p53. Zac1 enhanced the activity of transiently transfected reporter genes with arti®cial (pG13) and natural (p21 gene) promoters; transient expression of Zac1 also enhanced the expression of the native p21 gene in Hela cells. In cell lines lacking functional p53, Zac1 had little or no eect on the expression of the reporter genes, but if p53 expression was restored, then the Zac1 coactivator eect was observed (Figures 1 and 2) . Inhibition of p53 function by a dominant negative C-terminal fragment of p53 also prevented Zac1 from enhancing the activity of the p53-responsive reporter gene, and over-expression of wild type p53 restored the coactivator eect of Zac1 (Figure 3b) . If p53 response elements in the reporter genes were replaced with mutant p53 response elements that do not bind p53, then Zac1 had no eect even in cells containing p53 (Figure 3a) . These results indicate that Zac1 was not acting by direct enhancement of the reporter gene but through p53; the results are consistent with a model whereby Zac1 binds to p53 molecules bound to the enhancer elements of the p53-regulated genes and serves as a coactivator for p53. Zac1 bound p53 eciently in vitro and stimulated the activity of the transcriptional activation domain of p53 ( Figure 6) ; these results further support the coactivator model. How Zac1 enhances transcriptional activation after being recruited to the promoter by p53 is a subject for further investigation, but Zac1 has an autonomous activation domain which presumably interacts with some component of the transcription machinery (Huang and Stallcup, 2000) . Another model which cannot be ruled out at this time is that Zac1 may sequester or inactivate factors that somehow negatively regulate p53 activity.
The coactivator eect of Zac1 on the pG13-LUC reporter gene was observed in several dierent cell reporter plasmid (encoding luciferase and controlled by ®ve Gal4 response elements), 0.8 mg of pM-p53 or pM-p53 1 ± 127 (encoding Gal4 DBD fused to p53 or p53 1 ± 127 ), and where indicated (white histograms) 0.8 mg pSG5. lines. However, the magnitude of the coactivator eect varied dramatically in dierent cell lines, from several hundred-fold in HeLa cells to only 6 ± 10-fold in the other cell lines. This dierence indicates that other factors (e.g. expression of HPV-18 E6 protein in HeLa cells but not in the other cell lines) in¯uence the activity of Zac1.
Titration of p53 levels revealed that dierent levels of p53 had dramatically dierent eects on the coactivator activity of Zac1. Low levels of p53 were required for Zac1 activity on the pG13 promoter (Figures 1 and 2) , and transfection of low levels of p53 expression vector in various cell lines increased the eectiveness of Zac1 ( Figure 2) ; but in most cell lines high levels of p53 expression vector completely inhibited the Zac1 coactivator eect on pG13-LUC (Figure 2) . The mechanism by which p53 overexpression inhibits the coactivator eect of Zac1 remains to be elucidated, but p53 is known to inhibit the activity of nuclear receptors and some other transcriptional activators (Bhat et al., 1997; Yu et al., 1997) . It is possible that excess p53 could cause squelching by preventing Zac1 from associating with p53 bound to the reporter gene.
The ®nding of a very narrow optimum p53 concentration range to support Zac1's coactivator eect with the pG13 promoter is consistent with the existence of a ®nely balanced regulatory relationship between Zac1 and p53. Moreover, the fact that dramatic variations in the magnitude of Zac1 coactivator eects for p53 were observed, depending on the cell line and concentration of p53 used, indicates that other cellular components in¯uence the Zac1-p53 functional relationship and thus also supports the idea of a complex axis of regulatory components that aect p53 and Zac1 function.
One possible mechanism for the enhancement of p53 activity by Zac1 is an increase in the cellular level of p53, e.g. by stabilization of p53 protein. However, our data ( Figure 2 ) argue against this mechanism. When increasing amounts of a p53 expression vector were transfected, the reporter gene activity either reached a plateau (e.g. Figure 2a , closed circles) or reached an optimum and then declined at higher levels of p53 vector (Figure 2c, closed circles) . In either case, once the plateau or optimum p53 concentration was reached, additional p53 vector caused no further increase (Figure 2a ) or decreased reporter gene activity (Figure 2c ). However, even at supra-optimal concentrations of p53, adding a ®xed amount of Zac1 further enhanced reporter gene activity (Figure 2 , compare each open triangle with the vertically aligned closed circle). Thus, in cases where p53 levels were already beyond the optimum, the increase in reporter gene activity caused by Zac1 cannot be due to an increase in p53 levels. In other words, although Zac1 may possibly stabilize p53 (see discussion below about this issue in HeLa cells), an increase in p53 levels cannot fully explain the enhancement of p53 activity by Zac1, because we have shown that increasing the p53 level beyond the optimum does not increase reporter gene activity. Thus, our data indicate that Zac1 enhances p53 activity by serving as a coactivator.
Interactions between Zac1 and E6.18 proteins contribute to the enhancement of p53 function by Zac1 in HeLa cells
We have shown that Zac1 acted as a coactivator for p53, presumably because DNA-bound p53 recruits Zac1 to the promoter. However, the fact that the enhancing eect of Zac1 on p53 was so much larger in HeLa cells than in other cell lines (Figures 1 ± 3) indicates that the full eect of Zac1 involved more than just a simple p53-Zac1 interaction; rather, other cellular components can in¯uence the Zac1-p53 functional interaction. Our results indicate that the HPV E6.18 protein expressed in HeLa cells is a good candidate for such a protein. E6.18 protein is known to suppress p53 activity by several mechanisms: E6.18 induces ubiquitin-mediated degradation of p53, binds to p53 and prevents it from binding to genes with p53 response elements, and binds to coactivators CBP and p300 to inhibit their activities (Patel et al., 1999; Zimmerman et al., 1999; Thomas et al., 1999) . One possible mechanism for Zac1 coactivator function on p53-dependent promoters would be to prevent the E6.18-directed degradation of p53. However, while such a mechanism may be occurring, our data indicate that it is not sucient to explain entirely the dramatic coactivator eect of Zac1 on the pG13 promoter in HeLa cells; i.e. elevation of p53 levels by transient expression could not reproduce the eect of Zac1 (Figures 2d and 3a) (also see discussion in the preceding paragraph).
The fact that Zac1 bound to E6.18 protein and speci®cally disrupted E6.18-p53 binding in vitro ( Figure  7 ) provides an attractive mechanism for Zac1 to prevent p53 degradation and also to prevent E6.18 from inhibiting DNA binding and transcriptional activation by p53. This hypothesis was further supported by the demonstration that Zac1 interacted functionally with E6.18 protein. Zac1 partially reversed the inhibition of p53-dependent gene activity by E6.18 protein and altered the transcriptional activation activity of E6.18 fused to Gal4 DBD (Figure 8 ). Thus, our data indicate that the dramatic enhancement of p53 function by Zac1 in HeLa cells is probably due to multiple mechanisms, including a coactivator eect mediated by Zac1 binding to p53, and disruption of the E6-p53 complex, leading to stabilization of p53 and restoration of p53 binding to DNA. The discussion above indicates why none of the individual mechanisms alone can account for the full eect of Zac1 in HeLa cells and thus indicates that a combination of these mechanisms is at work.
Role for Zac1 in p53-dependent regulation of cell cycle and apoptosis When cells are subjected to stress (e.g. viral infection) or damage (e.g. DNA damage) that threatens to compromise the integrity of cellular reproduction, p53 is the focal point of the signaling pathways that sense the damage, and p53 plays a key role in deciding whether the cell will continue through the cell cycle, arrest the cell cycle to allow damage repair, or undergo apoptosis (May and May, 1999; Levine, 1997) . The location of p53 at such a key decision point suggests that p53 activity must be regulated precisely and in careful balance with all the impinging signaling pathways and any proteins that modulate or mediate p53 function. In fact, p53 activity, including its ability to bind DNA, has been shown to be regulated by a variety of covalent modi®cations and interactions with a variety of other proteins (May and May, 1999) . When tumor viruses infect cells they often interfere with p53 activity directly or indirectly and thereby promote unregulated cellular and viral proliferation in order to enhance viral replication eciency (Zimmermann et al., 1999) . Thus, in cells infected by such viruses, the viral oncoproteins (such as the HPV E6 proteins) that target and suppress p53 activity become part of the complex regulatory axis that revolves around p53. In the current study we identi®ed Zac1 as a new component of the complex p53 regulatory axis. Zac1 bound to and interacted functionally with p53 (Figure 6 ), E6.18 (Figure 7) , and CBP/p300 (Huang and Stallcup, 2000) . Thus Zac1 may cooperate with p53 to control cell cycle and apoptosis and may help cells to oppose the eects of viral oncoproteins.
Materials and methods
Plasmids
Luciferase reporter plasmids were described previously: pG13-LUC (El-Deiry et al., 1993); p21-LUC (Wu and Schonthal, 1997); GK1 (Paech et al., 1997) ; and pCMV-bgal (Hong et al., 1996) . pMG15-LUC (Kern et al., 1992) was a gift from Dr W El-Deiry (University of Pennsylvania).
A bacterial expression vector for His 6 -Zac1 was constructed by inserting an EcoRI ± HindIII fragment encoding mZac1b, ampli®ed by polymerase chain reaction (PCR), into pRSET(B). Bacterial Zac1 expression vector pGEX-2TK.mZac1b and mammalian Zac1 expression vector pSG5.HA-mZac1b were described previously (Huang and Stallcup, 2000) . cDNA clones encoding mouse p53 and various fragments of mouse p53 were obtained and ®tted with EcoRI and SalI sites by PCR ampli®cation from a mouse 17-day embryo cDNA library (Clontech). For expression of hemagglutinin A (HA) epitope-tagged proteins in mammalian cells or in cell free reactions, the PCRampli®ed cDNA fragments encoding p53 or its fragments were subcloned into the EcoRI ± XhoI sites of pSG5.HA (Chen et al., 1999) ; for expression in mammalian cells as fusion proteins with the yeast Gal4 DBD they were subcloned into the EcoRI ± SalI sites of pM (Clontech).
An EcoRI ± XhoI cDNA fragment encoding E6.18 protein was generated by PCR from reverse-transcribed total HeLa cell RNA and subcloned into the homologous sites in pSG5.HA and pGEX-4T1 and into the EcoRI ± SalI sites of pM.
Cell lines and transient transfection assays
HeLa cells were grown as previously described (Huang and Stallcup, 2000) . HCT116
p53+/+ and HCT116 p537/7 cell lines (Bunz et al., 1998) were grown in McCoy's 5A medium with 10% fetal bovine serum. T-47D human breast ductal carcinoma cells and MCF-7 human breast adenocarcinoma cells were obtained from the American Type Culture Collection and grown in RPMI 1640 medium and Minimal Essential Medium, respectively, supplemented with 10% fetal bovine serum. MDAH041, a post-crisis cell line derived from ®broblasts of a patient with Li ± Fraumeni syndrome (Little et al., 1987) , and MEF p537/7 cells (mouse embryo ®broblasts) (Harvey et al., 1993) were grown in Dulbecco's Modi®ed Eagle's Medium supplemented with 10% fetal bovine serum. Transient transfections in 6-well (3.3-cm diameter) culture dishes and determination of luciferase and bgal activities were described previously (Huang and Stallcup, 2000) . Luciferase activities are presented as relative light units (RLU) and are the means and standard deviations for three transfected cultures. Since the expression of many control reporter plasmids that are used to monitor transfection eciency is in¯uenced by Zac1 and p53, internal controls were not used. Instead, reproducibility was determined in multiple independent transfection experiments, and results of representative experiments are presented here.
Protein ± protein interaction assays in vitro Synthesis of labeled proteins from plasmids in vitro and binding analyses with GST fusion proteins were performed as described previously (Huang and Stallcup, 2000) . His 6 -tagged Zac1 protein was prepared with a His-Bind puri®cation kit (Novagen) according to the manufacturer's protocol.
Immunoblots
Transfection of COS-7 cells and immunoblots of transfected cell extracts were performed as described previously (Huang et al., 2000) , using antibodies against HA (3F10, Roche), p21 (C-19, Santa Cruz Biotechnology), and CARM1 (07-080, Upstate Biotechnology).
